What is the virus that is viral fever of humans and primates and that Triazavirin could have a potential application?
Triazavirin Triazavirin (TZV) is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has an azoloazine base structure, which represents a new structural class of non-nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including tick-borne encephalitis, and is also being investigated for potential application against Lassa fever and Ebola virus disease.
Bourbon virus Bourbon virus is an RNA virus in the genus "Thogotovirus" of the family "Orthomyxoviridae", which is similar to Dhori virus and Batken virus. It was first identified in 2014 in a man from Bourbon County, Kansas, United States, who died after being bitten by ticks. The case is the eighth report of human disease associated with a thogotovirus globally, and the first in the Western hemisphere. As of May 2015, a case was discovered in Stillwater, Oklahoma (the patient fully recovered) and relatively little is known about the virus. No specific treatment or vaccine is available. The virus is suspected to be transmitted by ticks or insects, and avoidance of bites is recommended to reduce risk of infection. In June 2017 a 58-year-old woman from Missouri died from an infection of the Bourbon virus after it had been misdiagnosed for a significant period of time.